Scarica l'app Stockscreener
547.09
0.50%
-2.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$549.87
Aprire:
$545.5
Volume 24 ore:
203.08K
Relative Volume:
0.40
Capitalizzazione di mercato:
$23.22B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
20.19
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+0.46%
1M Prestazione:
-3.16%
6M Prestazione:
+14.10%
1 anno Prestazione:
+67.92%
Intervallo 1D:
$545.11
$553.09
Intervallo di 1 settimana:
$534.97
$553.09
Portata 52W:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
547.10 | 23.34B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.76 | 49.29B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.915 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.45 | 39.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.25 | 33.30B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics CEO Rothblatt sells $5.47m in stock - Investing.com
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report? - Yahoo Finance
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock - Investing.com UK
United Therapeutics Q1 2026 slides: IPF breakthrough offsets revenue miss - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock By Investing.com - Investing.com Nigeria
United Therapeutics stock hits all-time high at 608.87 USD - Investing.com
UTHR Technical Analysis & Stock Price Forecast - Intellectia AI
UTHR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tectonic Therapeutic Stock Climbs as Broader Market Sinks - Bez Kabli
Xenotransplantation Explained: How Animal Organs Could Transform Medicine - News-Medical
Acute Respiratory Distress Syndrome Market to Grow - One News Page
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
United Therapeutics CFO James Edgemond sells $5.48m in shares - Investing.com UK
United Therapeutics CEO Rothblatt sells $863,947 in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock - Investing.com Nigeria
United Therapeutics CFO James Edgemond sells $5.48m in shares By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $863,947 in stock - Investing.com
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock By Investing.com - Investing.com South Africa
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? - The Motley Fool
Simplify Health Care ETF (PINK) vs. Vanguard Health Care ETF (VHT): A Detailed ComparisonNews and Statistics - IndexBox
Liquidia Sinks 5% After Recent Rally - Bez Kabli
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 19.47% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock - Insider Monkey
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock - Investing.com UK
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock By Investing.com - Investing.com South Africa
United Therapeutics Corporation (UTHR) Latest Stock News & Headlines - Yahoo Finance
United Therapeutics Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares - Investing.com India
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $5.4m in common stock By Investing.com - Investing.com India
United Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation Lags - Yahoo Finance
United Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EDGEMOND JAMES | CFO AND TREASURER |
Jun 04 '26 |
Sale |
546.28 |
10,000 |
5,462,824 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 04 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 04 '26 |
Sale |
546.33 |
9,500 |
5,190,128 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jun 04 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jun 04 '26 |
Sale |
547.07 |
8,300 |
4,540,642 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 03 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 03 '26 |
Sale |
547.61 |
9,500 |
5,202,271 |
40,513 |
1.32%
1.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):